Aktie BAFNAPH BAFNA PHARMACEUTICALS LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Bafna Pharmaceuticals Limited

Aktien

BAFNAPH

INE878I01022

BAFNAPH

Schlusskurs NSE India S.E.
Andere Börsenplätze
 00:00:00 01.07.2024 		% 5 Tage % 1. Jan.
79,24 INR +5,00 % Intraday Chart für Bafna Pharmaceuticals Limited +5,00 % -13,87 %
29.05. Bafna Pharmaceuticals Limited billigt die Ernennung von A. Mohanachandran zum Company Secretary und Compliance Officer CI
29.05. Bafna Pharmaceuticals Limited meldet Ergebnis für das vierte Quartal zum 31. März 2024 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Bafna Pharmaceuticals Limited Approves the Appointment of A. Mohanachandran as Company Secretary and Compliance Officer
Bafna Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024
Bafna Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024
Bafna Pharmaceuticals Limited Announces the Inauguration of New Quality Control Laboratory
Bafna Pharmaceuticals Limited Announces Resignation of Vishnu Vasudeva Kuppa as Company Secretary and Compliance Officer
Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Bafna Pharmaceuticals Resumes Commercial Production of Manufacturing Units in Chennai, India
Bafna Pharmaceuticals Limited Announces Commercial Production
Floods Disrupt Bafna Pharmaceuticals' Manufacturing Plant in Chennai, India
Bafna Pharmaceuticals Limited Announces Suspension of Chennai Production Activity Due to Impact of Michaung Cyclone
Bafna Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
Bafna Pharmaceuticals Limited Announces Resignation of Kamlesh Kumar Babulal as Non-Executive Independent Director from the Board
Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023
Bafna Pharmaceuticals Limited Approves Board Appointment
Bafna Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023
Bafna Pharmaceuticals Limited Announces Appointment Vishnu Vasudeva Kuppa as Company Secretary and Compliance Officer
Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
Bafna Pharmaceuticals Limited Announces Resignation of Atul Sachdeva as Director
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. BAFNAPH Aktie
  4. Nachrichten Bafna Pharmaceuticals Limited
  5. Andere Sprachen